PTK5 Inhibitors
1 drugsAbout PTK5
PTK5, or protein tyrosine kinase 5, is a protein kinase that regulates cellular processes through phosphorylation, impacting cell signaling pathways. While its precise function is still being elucidated, PTK5's role in signaling cascades makes it a potential therapeutic target.
PTK5 is targeted by one FDA-approved drug, STIVARGA, in the 'other' therapeutic area category. Currently, there is no genetic evidence data available linking PTK5 to specific diseases, highlighting an opportunity for further research.
STIVARGA (Bayer) is the only approved drug targeting PTK5, approved in 2012 and indicated for three conditions. The drug is a small molecule, representing 100% of the modality landscape for this target.
Top PTK5 Drugs
Bayer is the only company with an approved drug targeting PTK5.
Low competition may present an opportunity, but also indicates potential challenges in the target's viability.
PTK5 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PTK5, using small molecule modality.
Consider exploring alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
PTK5 Clinical Trials 224 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PTK5. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 40 | 10 | 14 | 80% |
| Phase 2 | 127 | 50 | 24 | 53 | 68% |
| Phase 3 | 28 | 13 | 6 | 9 | 68% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved PTK5 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PTK5. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PTK5 Drug Approval Timeline (2012 - 2012)
The first and only drug, STIVARGA, was approved in 2012.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new PTK5-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 132 (29 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PTK5. A trial counts if an approved drug acting on PTK5 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.